Terms: = Liver cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
118 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive molecular analysis identifies ret alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
[TBL] [Abstract] [Full Text] [Related]
5. Safety of Sonazoid in Assisting High-Intensity Focused Ultrasound Ablation Therapy for Advanced liver Malignant Lesions: A Single-Arm Clinical Study.
Zhou H; Li F; Luo L; Xiong X; Zhou K; Zhu H; Zhang J; Li P
Ultrasound Med Biol; 2024 Jan; 50(1):134-141. PubMed ID: 37865612
[TBL] [Abstract] [Full Text] [Related]
6. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract] [Full Text] [Related]
7. The action and resistance mechanisms of Lenvatinib in liver cancer.
Buttell A; Qiu W
Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
[TBL] [Abstract] [Full Text] [Related]
8. [Chylous ascites in NSCLC: It is not always malignant].
Uhlenbruch M; Bärmann MK; Bertram V; Krüger S
Pneumologie; 2023 Dec; 77(12):1013-1015. PubMed ID: 37402387
[TBL] [Abstract] [Full Text] [Related]
9. Selpercatinib monotherapy in a Chinese patient with ret fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBretTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract] [Full Text] [Related]
10. An electrochemiluminescence resonance energy transfer biosensor based on Luminol-LDH and CuS@Pt for detection of alpha-fetoprotein.
Liang W; Cong B; Lai W; Jiang M; Ma C; Zhao C; Jiang W; Zhang S; Qi Y; Hong C
Talanta; 2023 Aug; 261():124669. PubMed ID: 37210917
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.
Ni B; He X; Zhang Y; Wang Z; Dong Z; Xia X; Zhao G; Cao H; Zhu C; Li Q; Liu J; Chen H; Zhang Z
Cell Oncol (Dordr); 2023 Apr; 46(2):315-330. PubMed ID: 36808605
[TBL] [Abstract] [Full Text] [Related]
12. HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired ret gene fusion and TP53 gene mutation are potential reasons.
Jiang F; Lai J; Zhuo X; Liu L; Yang Y; Zhang J; Zhao J; Xu W; Wang J; Wang C; Fu G
Anticancer Drugs; 2023 Nov; 34(10):1196-1201. PubMed ID: 36689646
[TBL] [Abstract] [Full Text] [Related]
13. The clinical value of identifying genetic abnormalities that can be targeted in cholangiocarcinomas.
Testa U; Pelosi E; Castelli G
Expert Rev Anticancer Ther; 2023 Feb; 23(2):147-162. PubMed ID: 36654529
[TBL] [Abstract] [Full Text] [Related]
14. retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts.
Zhu W; Qiu Z; Yan H; Zhong Z; Jiang W; Zhang F; Gao F
Diagn Interv Radiol; 2022 Nov; 28(6):616-620. PubMed ID: 36550763
[TBL] [Abstract] [Full Text] [Related]
15. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
16. Rational development of combination therapies for biliary tract cancers.
Harding JJ; Khalil DN; Fabris L; Abou-Alfa GK
J Hepatol; 2023 Jan; 78(1):217-228. PubMed ID: 36150578
[TBL] [Abstract] [Full Text] [Related]
17. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract] [Full Text] [Related]
18. Hepatoid tumors of the gastrointestinal/pancreatobiliary district: morphology, immunohistochemistry, and molecular profiles.
Mattiolo P; Scarpa A; Luchini C
Hum Pathol; 2023 Feb; 132():169-175. PubMed ID: 35714834
[TBL] [Abstract] [Full Text] [Related]
19. Application of histology-agnostic treatments in metastatic colorectal cancer.
Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
[TBL] [Abstract] [Full Text] [Related]
20. Novel Therapeutics and Treatment Strategies for Medullary Thyroid cancer.
Walgama E; Busaidy N; Zafereo M
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):379-389. PubMed ID: 35662447
[TBL] [Abstract] [Full Text] [Related]
[Next]
